China Pharma (CPHI) 10-K 1 Apr 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 24, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	China Pharma Holdings, Inc.
Entity Central Index Key	0001106644
Entity File Number	001-34471
Entity Tax Identification Number	73-1564807
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 3,896,941
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	Second Floor, No. 17, Jinpan Road
Entity Address, Address Line Two	Haikou
Entity Address, City or Town	Hainan Province
Entity Address, Country	CN
Entity Address, Postal Zip Code	570216
Entity Phone Fax Numbers [Line Items]
City Area Code	(011)
Local Phone Number	86 898-6681-1730
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	CPHI
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		14,816,865

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Auditor [Table]
Auditor Name	BF Borgers CPA PC
Auditor Firm ID	5041
Auditor Location	Lakewood, CO

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 1,423,838	$ 2,029,971
Banker’s acceptances	65,915	13,784
Trade accounts receivable, less allowance for doubtful accounts of $13,786,074 and $16,739,527, respectively	504,448	421,531
Other receivables, less allowance for doubtful accounts of $27,017 and $27,149, respectively	157,944	29,139
Advances to suppliers	2,013	444,637
Inventory	3,732,517	2,947,787
Prepaid expenses	110,258	77,697
Total Current Assets	5,996,933	5,964,546
Property, plant and equipment, net	7,100,425	9,973,065
Operating lease right of use asset	116,610	39,046
Intangible assets, net	3,255,232	1,807,486
TOTAL ASSETS	16,469,200	17,784,143
Current Liabilities:
Trade accounts payable	966,420	667,082
Accrued expenses	298,829	404,807
Other payables	2,282,692	2,390,063
Advances from customers	90,507	520,295
Operating lease liability	77,727	40,445
Current portion of lines of credit	1,030,680	2,440,915
Convertible, redeemable note payable, net of issue discount	940,000	3,800,000
Total Current Liabilities	6,820,664	12,739,447
Non-current Liabilities:
Operating lease liability, net of current portion	39,910
Lines of credit, net of current portion	1,411,891
Deferred tax liability	742,114	754,698
Total Liabilities	9,014,579	13,494,145
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 10,625,788 shares and 1,498,180 shares issued and outstanding, respectively	10,625	1,498
Additional paid-in capital	35,282,256	28,926,931
Retained deficit	(39,290,314)	(36,211,496)
Accumulated other comprehensive income	11,452,054	11,573,065
Total Stockholders’ Equity	7,454,621	4,289,998
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	16,469,200	17,784,143
Related Party
Current Liabilities:
Borrowings from related parties	$ 1,133,809	$ 2,475,840

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts (in Dollars)	$ 13,786,074	$ 16,739,527
Other receivables, allowance for doubtful accounts (in Dollars)	$ 27,017	$ 27,149
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	10,625,788	1,498,180
Common stock, shares outstanding	10,625,788	1,498,180

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 7,011,299	$ 8,104,092
Cost of revenue	7,292,384	8,598,008
Gross (loss) profit	(281,085)	(493,916)
Operating expenses:
Selling expenses	780,328	1,069,785
General and administrative expenses	1,466,084	1,893,269
Research and development expenses	240,080	185,858
Bad debt benefit	(15,757)	(93,851)
Total operating expenses	2,470,735	3,055,061
Loss from operations	(2,751,820)	(3,548,977)
Other income (expense):
Interest income	6,602	10,755
Interest expense	(333,600)	(434,619)
Net other expense	(326,998)	(423,864)
Loss before income taxes	(3,078,818)	(3,972,841)
Income tax expense
Net loss	(3,078,818)	(3,972,841)
Other comprehensive income (loss) - foreign currency translation adjustment	(121,011)	(990,764)
Comprehensive loss	$ (3,199,829)	$ (4,963,605)
Loss per share:
Basic (in Dollars per share)	$ (0.91)	$ (3.78)
Weighted average shares outstanding (in Shares)	3,383,573	1,051,371

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Diluted	$ (0.91)	$ (3.78)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2021	$ 947	$ 25,691,760	$ (32,238,655)	$ 12,563,829	$ 6,017,881
Balance (in Shares) at Dec. 31, 2021	946,791
Issuance of common stock for intangible assets	$ 310	1,707,142			1,707,452
Issuance of common stock for intangible assets (in Shares)	310,446
Stock option compensation		36,270			36,270
Issuance of common stock for services	$ 6	41,994			42,000
Issuance of common stock for services (in Shares)	6,000
Conversions of note payable to common stock	$ 235	1,449,765			1,450,000
Conversions of note payable to common stock (in Shares)	234,943
Net loss for the year			(3,972,841)		(3,972,841)
Foreign currency translation adjustment				(990,764)	(990,764)
Balance at Dec. 31, 2022	$ 1,498	28,926,931	(36,211,496)	11,573,065	$ 4,289,998
Balance (in Shares) at Dec. 31, 2022	1,498,180				1,498,180
Issuance of common stock for intangible assets	$ 3,000	1,647,000			$ 1,650,000
Issuance of common stock for intangible assets (in Shares)	3,000,000
Conversion of related party note and interest	$ 2,751	1,851,701			1,854,452
Conversion of related party note and interest (in Shares)	2,751,412
Share rounding due to reverse split	$ 14	(14)
Share rounding due to reverse split (in Shares)	14,085
Conversions of note payable to common stock	$ 3,362	2,856,638			2,860,000
Conversions of note payable to common stock (in Shares)	3,362,111
Net loss for the year			(3,078,818)		(3,078,818)
Foreign currency translation adjustment				(121,011)	(121,011)
Balance at Dec. 31, 2023	$ 10,625	$ 35,282,256	$ (39,290,314)	$ 11,452,054	$ 7,454,621
Balance (in Shares) at Dec. 31, 2023	10,625,788				10,625,788

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net loss	$ (3,078,818)	$ (3,972,841)
Depreciation and amortization	2,753,653	2,700,533
Bad debt (benefit) expense	(15,757)	(93,851)
Stock and stock option compensation		78,270
Loss on disposal of property, plant & equipment	45,385
Changes in assets and liabilities:
Trade accounts and other receivables	(938,021)	(170,194)
Advances to suppliers	437,431	(459,959)
Inventory	(25,032)	689,104
Trade accounts payable	312,045	(187,734)
Other payables and accrued expenses	257,778	692,190
Advances from customers	(423,261)	339,659
Prepaid expenses	(25,089)	(24,722)
Net Cash Used in Operating Activities	(699,686)	(409,545)
Cash Flows from Investing Activities:
Purchases of property and equipment	(11,517)	(401,964)
Net Cash Used in Investing Activities	(11,517)	(401,964)
Cash Flows from Financing Activities:
Payments of line of credit	(1,490,049)	(2,140,921)
Proceeds from lines of credit	1,532,622	564,965
Borrowings and interest from related party	30,572	28,962
Repayments to related party		(223,013)
Net Cash (Used In) Provided By Financing Activities	73,145	(1,770,007)
Effect of Exchange Rate Changes on Cash	31,925	(247,573)
Net Increase in Cash, Cash Equivalents and Restricted Cash	(606,133)	(2,829,089)
Cash and Cash Equivalents at Beginning of Period	2,029,971	4,859,060
Cash, Cash Equivalents and Restricted Cash at End of Period	1,423,838	2,029,971
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	92,439	141,797
Supplemental Noncash Investing and Financing Activities:
Accounts receivable collected with banker’s acceptances	865,733	503,383
Inventory purchased with banker’s acceptances	813,105	575,713
Right-of-use assets obtained in exchange for operating lease obligations	156,273
Common stock issued for intangible assets	1,650,000	1,707,452
Conversion of related party note and interest to common stock	$ 1,854,542

Organization and Significant Ac

Organization and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Organization and Significant Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern As of December 31, 2023, the Company had cash and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer (“Chairperson Li”) has advanced an aggregate of $1,133,809 as of December 31, 2023 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Reverse Stock Split Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. Accounting Estimates Cash and Cash Equivalents Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December 31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts. Advances to Suppliers and Advances from Customers Inventory – Leases – At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (“Short-Term Leases”). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. Valuation of Long-Lived Assets Property, Plant and Equipment Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company’s contracts are fixed price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon buyer’s designated carrier or the buyer picks up the goods at the Company’s warehouse. For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year. These advances total $90,507 and $520,295 and are recorded as a liability on the accompanying balance sheet as “Advances from customers” as of December 31, 2023 and 2022, respectively. The subsequently recognized revenue was $81,456as of March 29, 2024. Cost of Revenues Research and Development Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy. Interest Rate Risk Basic and Diluted Loss per Common Share As of December 31, 2023, the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: December 31, December 31, 2023 2022 Raw materials 1,849,213 1,839,641 Work in process 413,597 557,146 Finished goods 1,469,707 551,000 Total Inventory $ 3,732,517 $ 2,947,787

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: December 31, December 31, 2023 2022 Permit of land use $ 397,684 $ 404,427 Building 9,234,836 9,391,433 Plant, machinery and equipment 27,170,123 27,780,585 Motor vehicle 303,697 438,138 Office equipment 388,740 308,847 Total 37,495,080 38,323,430 Less: accumulated depreciation (30,394,655 ) (28,350,365 ) Property, plant and equipment, net $ 7,100,425 $ 9,973,065 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $2,529,858 and $2,663,975 for the years ended December 31, 2023 and 2022, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the NMPA, the intellectual property acquired from Chengdu Bonier Medical Technology Development Co., Ltd. (“Bonier Agreement”) and the Technology Transfer Agreement (the “ Agreement Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $223,796 and $36,558 for the years ended December 31, 2023 and 2022, respectively which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. On December 15, 2023, the Company entered into a Technology Transfer Agreement (the “Agreement”) with Tao Liu (the “Transferor”). The Transferor owns an invention patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the “Invention Patent”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. Effective December 15, 2023 China Pharma issued 3,000,000 shares of its common stock valued at $1,650,000 based on the closing market price of its common stock of $0.55 per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2023. The value of the intangible asset will be amortized over its remaining useful life of approximately 14.8 years. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual basis to the Transferor. On November 28, 2022, the Company entered into a Technology Transfer Contract (the “Bonier Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”). Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the “Utility Model Patent”) and applied for an invention patent (the “Invention Patent”) at the same time. Pursuant to the Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical invention and the Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services, with a term of ten years. Effective November 28, 2022 the Company issued 310,446 share of its common stock valued at $1,707,452 based on the closing market price of its common stock of $5.50 per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2022. The value of the intangible asset will be amortized over its remaining useful life of approximately 9.7 years. The Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent on the successful authorization of the above mentioned Invention Patent. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the years ended December 31, 2023 and 2022, respectively. Intangible assets consisted of the following: December 31, December 31, 2023 2022 NMPA approved medical formulas $ 4,766,353 $ 4,847,176 Technology from Bonier 1,726,497 1,707,452 Invention Patent 1,653,028 - Accumulated amortization (4,890,646 ) (4,747,142 ) Net carrying amount $ 3,255,232 $ 1,807,486 The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows: Year Amount 2024 327,050 2025 321,235 2026 292,156 2027 292,156 2028 292,156 Thereafter 1,730,479 Total $ 3,255,232

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2023
Other Payables [Abstract]
OTHER PAYABLES	NOTE 5 – OTHER PAYABLES Other Payables consisted of the following: December 31, December 31, 2023 2022 Compensation payable to officer 1,243,506 951,506 Compensation and interest to related parties $ 12,000 $ 372,578 Business taxes and other 1,027,186 1,065,979 Total Other Payables $ 2,282,692 $ 2,390,063

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company’s board of directors (“Board”) had previously advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2022 which is recorded as “Other payables – related parties” on the accompanying condensed consolidated balance sheets. The advances bore interest at a rate of 1.0% per year. Total interest expense years ended December 31, 2023 and 2022 was $6,773 and $13,546, respectively. Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $12,000 and $372,578 as of December 31, 2023 and 2022, respectively. On August 23, 2023, the director entered into a certain debt transfer agreement with Chairperson Li, pursuant to which the rights to collect a total amount of $1,854,452 were assigned to Chairperson Li. On September 28, 2023, Chairperson Li entered into a certain loan settlement agreement, pursuant to which both parties agreed to convert the aggregate amount of $1,854,452 owed by the Company into 2,751,412 shares of restricted common stock of the Company. Such issuance was completed on September 29, 2023. The Company received advances totaling $2,928 and $0 and repaid $0 and $223,013 of the advances during the years ended December 31, 2023 and 2022, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,121,273 and $1,425,123 and are recorded as Other payables – related parties on the accompanying condensed consolidated balance sheets as of December 31, 2021 and 2020, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2023. Total interest expense related to the loan for the years ended December 31, 2023 and 2022 was $27,644 and $28,962, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying consolidated balance sheet totaling $1,243,506 and $951,506 as of December 31, 2023 and 2022, respectively.

Lines of Credit and Constructio

Lines of Credit and Construction Loan Facility	12 Months Ended
	Dec. 31, 2023
Lines of Credit and Construction Loan Facility [Abstract]
LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY	NOTE 7 – LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY Lines of Credit On June 25, 2021 the Company entered into a loan with Bank of Communications bearing an interest rate of 4.17%. The Company paid all principal and interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing interest at 4.17% and due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line of credit for an aggregate amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately $0.56 million) on December 30, 2022. On February 24, 2023 the Company received an advance on the line in the amount of RMB 3,500,000 (approximately $0.51 million). The Company has no further availability on this line of credit. The line of credit was payable on December 20, 2023. The line of credit was paid in full on December 15, 2023. On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest rate of 3.9% and is due December 15, 2024. The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. In September, 2021 the Company repaid the line of credit in full. Also in September, 2021 the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million). The loan bears interest at the rate of 4.50% per annum. The line of credit was due on September 2, 2022. The line of credit was paid in full on September 6, 2022. On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears interest at a rate of 4.5% and is due on September 7, 2023 On September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per annum. The line of credit was paid in full on the due date of September 18, 2022. On September 30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at the rate of 3.45% and was due September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a three-year revolving loan and received proceeds of RMB 10,000,000 (approximately $1.4 million). The interest rate for the loan is 3.35% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month anniversary of the loan. The loan is due on September 24, 2026. Principal payments required for the remaining terms of the lines of credit as of December 31, 2023 are as follows: Year Lines of 2024 $ 2,442,571 $ 2,442,571 In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The loan bore interest at a rate of 4.25% per annum. Advances on the line of credit were due two years from the date of the advance. A third party company had guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the line of credit. Total interest expense under this facility for the years ended December 31, 2022 was $12,063. The Company repaid the remaining RMB 5,900,000 (approximately $0.85) during the year ended December 31, 2022 as per the repayment schedule in full satisfaction of the line of credit. Fair Value of Lines of Credit

Convertible Note Payable

Convertible Note Payable	12 Months Ended
	Dec. 31, 2023
Convertible Note Payable [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 8 – CONVERTIBLE NOTE PAYABLE On November 17, 2021, China Pharma entered into a Securities Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note (the “Note”) to an institutional accredited investor Streeterville Capital, LLC (the “Investor”). The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13, 2023 China Pharma entered into an Amendment (the “Amendment”) with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of $65,639, representing 2.0% of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition, China Pharma decreased the price at which the Investor can convert the balance from 85% to 82% of the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, and assumed an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. The Note was originally convertible into 70,000 shares of China Pharma’s common stock at a price of $75.00 per share through April 19, 2022. Thereafter, the Note was convertible into 35,000 shares at a price of $150.00 per share. As of December 31, 2023 the Note is convertible into 6,267 shares of common stock. Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor’s consent for certain fundamental transactions such as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor’s prior written consent will be deemed an Event of Default. Investor may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date, as defined in the Note, upon three trading days’ notice, in cash or converting into shares of China Pharma’s common stock, at a price equal to 82% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor’s consent. At inception, the Note was redeemable into 176,229 shares based on the lowest volume weighted average price of $29.79085 on the inception date of November 19, 2021. As of December 31, 2023, the Note was redeemable into 2,159,964 shares of common stock based on 82% of the lowest volume weighted average price of $0.436 on that date. Total interest expense for the years ended December 31, 2023 and 2022 was $206,744 and $250,314, respectively. 2023 Redemptions On January 5, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $3.815, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 39,319 shares of common stock to the Investor on January 6, 2023. On January 18, 2023 the Investor delivered its notice of redemption for $250,000 of the Note and related interest at the conversion price of $3.815, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 65,531 shares of common stock to the Investor on January 19, 2023. On March 2, 2023 the Investor delivered its notice of redemption for $250,000 of the Note and related interest at the conversion price of $2.875, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 86,957 shares of common stock to the Investor on March 8, 2023. On April 7, 2023 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the conversion price of $1.404, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 142,450 shares of common stock to the Investor on April 13, 2023. On May 1, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $1.322, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 113,465 shares of common stock to the Investor on May 3, 2023. On May 24, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $1.2435, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 120,628 shares of common stock to the Investor on May 25, 2023. On June 6, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $1.328, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 112,952 shares of common stock to the Investor on June 13, 2023. On June 23, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $1.4225, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, China Pharma issued a total of 105,448 shares of common stock to the Investor on June 27, 2023. On August 9, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $1.0715, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 139,991 shares of common stock to the Investor on August 11, 2023. On August 21, 2023 the Investor delivered its notice of redemption for $245,000 of the Note and related interest at the conversion price of $1.0715, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 228,652 shares of common stock to the Investor on August 22, 2023. On September 1, 2023, the Investor delivered its notice of redemption for $140,000 of the Note and related interest at the conversion price of $0.666, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 210,211 shares of common stock to the Investor on September 6, 2023. On September 12, 2023, the Investor delivered its notice of redemption for $75,000 of the Note and related interest at the conversion price of $0.579, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 129,534 shares of common stock to the Investor on September 13, 2023. On October 6, 2023 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the conversion price of $0.546, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 183,150 shares of common stock to the Investor on October 9, 2023. On October 12, 2023 the Investor delivered its notice of redemption for $115,000 of the Note and related interest at the conversion price of $0.513, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 224,172 shares of common stock to the Investor on October 13, 2023. On October 17, 2023 the Investor delivered its notice of redemption for $115,000 of the Note and related interest at the conversion price of $0.513, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 224,172 shares of common stock to the Investor on October 17, 2023. On November 6, 2023 the Investor delivered its notice of redemption for $80,000 of the Note and related interest at the conversion price of $0.3765, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 212,444 shares of common stock to the Investor on November 7, 2023. On November 29, 2023 the Investor delivered its notice of redemption for $125,000 of the Note and related interest at the conversion price of $0.368, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 339,674 shares of common stock to the Investor on November 30, 2023. On November 30, 2023 the Investor delivered its notice of redemption for $115,000 of the Note and related interest at the conversion price of $0.368, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 312,500 shares of common stock to the Investor on December 1, 2023. On December 13, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.4045, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 370,828 shares of common stock to the Investor on December 18, 2023. Subsequent to December 31, 2023 the Investor delivered additional notices of redemption as discussed in Note 14. 2022 Redemptions On March 21, 2022 the Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of $15.565 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 6,425 shares of common stock to the Investor on March 23, 2022. On March 30, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the price of $15.645, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 12,874 shares of common stock to the Investor on March 31, 2022. On June 13, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the price of $9.90, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 20,202 shares of common stock to the Investor on June 13, 2022. On August 3, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the conversion price of $8.775, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 22,792 shares of common stock to the Investor on August 4, 2022. On October 17, 2022 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the conversion price of $5.60, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 17,857 shares of common stock to the Investor on October 18, 2022. On December 1, 2022 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the conversion price of $4.145, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 24,126 shares of common stock to the Investor on December 2, 2022. On December 5, 2022 the Investor delivered its notice of redemption for $310,000 of the Note and related interest at the conversion price of $4.145, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 74,789 shares of common stock to the Investor on December 6, 2022. On December 13, 2022 the Investor delivered its notice of redemption for $90,000 of the Note and related interest at the conversion price of $4.55, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 19,781 shares of common stock to the Investor on December 14, 2022. On December 14, 2022 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $4.145, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 36,181 shares of common stock to the Investor on December 15, 2022.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the years ended December 31, 2023 and 2022, operating lease cost was $77,265 and $78,092, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $80,647 and $82,015, respectively. As of December 31, 2023 and 2022, the Company reported operating lease right of use assets of $116,610 and $39,046, respectively and operating use liabilities of $117,637 and $40,445, respectively. As of December 31, 2023, its operating leases had a weighted average remaining lease term of 1.50 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month periods ended December 31: 2024 $ 80,647 2025 $ 40,324 Total undiscounted cash flows 120,971 Less: Imputed interest (3,334 ) 117,637 Less: Operating lease liabilities, current portion (77,727 ) Operating lease liabilities, net of current portion $ 39,910 The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2020 through December 31, 2023 and the Chinese income tax return for the year ended December 31, 2023 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the years ended December 31, 2023 and 2022, respectively due to continued net losses of the Company. Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes: Years Ended December 31, 2023 2022 (Benefit) tax at statutory rate of 25% $ (769,704 ) $ (973,717 ) Prior year refund received - - Other, primarily the difference in U.S. tax rates 3,382 8,416 Change in valuation allowance 766,322 965,301 Income tax expense $ - $ - The temporary differences which give rise to the deferred income tax assets and liability are as follows: December 31, 2023 2022 Deferred income tax assets: Allowance for doubtful trade receivables $ 3,446,519 $ 4,184,882 Allowance for doubtful other receivables 6,754 6,787 Inventory obsolescence reserve 32,355 34,921 Stock compensation 3,201 3,201 Expenses not deductible in current year 1,069,198 1,087,328 Advances for intangible assets impairment 9,619,060 9,782,172 Lease liability, net 257 349 PRC net operating loss carry forward 5,275,411 5,036,114 U.S. net operating loss carry forward 2,078,262 1,849,800 Total deferred income tax assets 21,531,017 21,985,554 Valuation allowance (21,531,017 ) (21,985,554 ) Net deferred income tax asset $ - $ - Deferred income tax liability: Intangible assets $ 742,114 $ 754,698 As of December 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $21.1 million which are available to offset any future taxable income through 2028. Approximately $3.4 million of these carryforwards expired in December 2023. The Company also has net operating losses for United States federal income tax purposes of approximately $9.9 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2023 and 2022. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,531,017 and $21,467,355 as of December 31, 2023 and 2022, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds as of December 31, 2023 and 2022. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at December 31, Reporting Date Using Description 2023 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 65,915 $ - $ 65,915 $ - Total $ 65,915 $ - $ 65,915 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2022 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 13,784 $ - $ 13,784 $ - Total $ 13,784 $ - $ 13,784 $ -

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS’ EQUITY The Company is authorized to issue 500,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board. According to relevant PRC laws, companies registered in the PRC, including the Company’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000 at December 31, 2023 and 2022. Effective March 6, 2024, the Company implemented a 1-for -5 reverse stock split as more fully discussed in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split. Effective March 6, 2023 China Pharma implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and China Pharma’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of China Pharma’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in China Pharma’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying consolidated financial statements. 2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares of common stock. Through December 31, 2023, there were 84,700 shares of stock and stock options granted and outstanding under the Plan. A total of 13,300 options were outstanding as of December 31, 2023 under the Plan. As such, there are 482,000 additional units available for issuance under the Plan. There were no issuances of securities from the Plan for the year ended December 31, 2023 and as such, no compensation expense was recognized for the period. On October 3, 2022 the Company issued 6,000 shares of common stock pursuant to a contract with a consultant to the Company for services. The Company recorded compensation expense totaling $42,000 based on the closing market price of its common stock of $7.00 per share on the issuance date. The contract also calls for the issuance of up to 18,000 additional shares of common stock contingent upon the achievement of certain milestones as described in the contract. At December 31, 2023 these milestones had not been met. On October 4, 2022 the Company issued an option to purchase 12,000 shares of common stock at an exercise price at $28.00 per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires on October 3, 2027. On September 9, 2021 the Company issued an aggregate of 35,200 fully vested shares of common stock at the price of $33.50 per share, representing the closing market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan, as amended, to partially offset certain unpaid cash compensation totaling $1,179,200. Also on September 9, 2021 the Company issued an option to purchase 1,300 shares of common stock at an exercise price at $73.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. On December 23, 2020 the Board approved the issuance of 40,000 shares of common stock from the Company’s 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer. As of December 31, 2023, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Risks & Uncertainties

Risks & Uncertainties	12 Months Ended
	Dec. 31, 2023
Risks & Uncertainties [Abstract]
RISKS & UNCERTAINTIES	NOTE 13 – RISKS & UNCERTAINTIES Current vulnerability due to certain concentrations For the year ended December 31, 2023, no customer accounted for more than 10% of sales and two customers accounted for 62.59% and 13.5% of accounts receivable. One suppliers accounted for 13.8% of raw material purchases, and three different products accounted for 29.2%, 27.3% and 12.5% of revenue. For the year ended December 31, 2022, no customer accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and 10.4% of accounts receivable. Two suppliers accounted for 21.7% and 11.1% of raw material purchases, and three different products accounted for 25.0%, 22.8% and 13.9% of revenue. Nature of Operations Impact from the New Coronavirus Global Pandemic (“COVID-19”) Economic environment - In addition, all of the Company’s revenue is denominated in the PRC’s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS On February 2, 2024, the Company entered into a Technology Transfer Agreement with Lihua Li (the “Transferor”). The Transferor owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the “Invention Patent”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application. The aggregate transfer price as contemplated by the Agreement is $1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at $0.455 per share based on the closing market price of the Company’s common stock as of that date. During ten years since the product launches to the market, if and only if the product generates profit, Helpson shall pay 10% of the net profit of the sales in cash on an annual basis to the Transferor. Effective March 6, 2024 the Company implemented a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and the Company’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for the years ended December 31, 2023 and 2022. On January 11, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. On February 1, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024. On February 16, 2024 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,078,818)	$ (3,972,841)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Organization and Significant Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.
Liquidity and Going Concern	Liquidity and Going Concern As of December 31, 2023, the Company had cash and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer (“Chairperson Li”) has advanced an aggregate of $1,133,809 as of December 31, 2023 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Reverse Stock Split	Reverse Stock Split
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.
Accounting Estimates	Accounting Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Trade Accounts Receivable and Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December 31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.
Advances to Suppliers and Advances from Customers	Advances to Suppliers and Advances from Customers
Inventory	Inventory –
Leases	Leases – At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (“Short-Term Leases”). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets
Property, Plant and Equipment	Property, Plant and Equipment
Revenue Recognition	Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company’s contracts are fixed price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon buyer’s designated carrier or the buyer picks up the goods at the Company’s warehouse.
Cost of Revenues	Cost of Revenues
Research and Development	Research and Development
Credit Risk	Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.
Interest Rate Risk	Interest Rate Risk
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share As of December 31, 2023, the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
Schedule of Inventory	Inventory consisted of the following: December 31, December 31, 2023 2022 Raw materials 1,849,213 1,839,641 Work in process 413,597 557,146 Finished goods 1,469,707 551,000 Total Inventory $ 3,732,517 $ 2,947,787

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following: December 31, December 31, 2023 2022 Permit of land use $ 397,684 $ 404,427 Building 9,234,836 9,391,433 Plant, machinery and equipment 27,170,123 27,780,585 Motor vehicle 303,697 438,138 Office equipment 388,740 308,847 Total 37,495,080 38,323,430 Less: accumulated depreciation (30,394,655 ) (28,350,365 ) Property, plant and equipment, net $ 7,100,425 $ 9,973,065
Schedule of Estimated Useful Lives of The Assets	Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: December 31, December 31, 2023 2022 NMPA approved medical formulas $ 4,766,353 $ 4,847,176 Technology from Bonier 1,726,497 1,707,452 Invention Patent 1,653,028 - Accumulated amortization (4,890,646 ) (4,747,142 ) Net carrying amount $ 3,255,232 $ 1,807,486
Schedule of Aggregate Annual Amortization Expense	The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows: Year Amount 2024 327,050 2025 321,235 2026 292,156 2027 292,156 2028 292,156 Thereafter 1,730,479 Total $ 3,255,232

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Other Payables [Abstract]
Schedule of Other Payables	Other Payables consisted of the following: December 31, December 31, 2023 2022 Compensation payable to officer 1,243,506 951,506 Compensation and interest to related parties $ 12,000 $ 372,578 Business taxes and other 1,027,186 1,065,979 Total Other Payables $ 2,282,692 $ 2,390,063

Lines of Credit and Construct_2

Lines of Credit and Construction Loan Facility (Tables)	12 Months Ended
	Dec. 31, 2023
Lines of Credit and Construction Loan Facility [Abstract]
Schedule of principal payments	Principal payments required for the remaining terms of the lines of credit as of December 31, 2023 are as follows: Year Lines of 2024 $ 2,442,571 $ 2,442,571

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Operating Lease Liabilities	Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month periods ended December 31: 2024 $ 80,647 2025 $ 40,324 Total undiscounted cash flows 120,971 Less: Imputed interest (3,334 ) 117,637 Less: Operating lease liabilities, current portion (77,727 ) Operating lease liabilities, net of current portion $ 39,910

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Income Taxes Calculated at the Federal Statutory Rates	Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes: Years Ended December 31, 2023 2022 (Benefit) tax at statutory rate of 25% $ (769,704 ) $ (973,717 ) Prior year refund received - - Other, primarily the difference in U.S. tax rates 3,382 8,416 Change in valuation allowance 766,322 965,301 Income tax expense $ - $ -
Schedule of Deferred Income Tax Assets and Liability	The temporary differences which give rise to the deferred income tax assets and liability are as follows: December 31, 2023 2022 Deferred income tax assets: Allowance for doubtful trade receivables $ 3,446,519 $ 4,184,882 Allowance for doubtful other receivables 6,754 6,787 Inventory obsolescence reserve 32,355 34,921 Stock compensation 3,201 3,201 Expenses not deductible in current year 1,069,198 1,087,328 Advances for intangible assets impairment 9,619,060 9,782,172 Lease liability, net 257 349 PRC net operating loss carry forward 5,275,411 5,036,114 U.S. net operating loss carry forward 2,078,262 1,849,800 Total deferred income tax assets 21,531,017 21,985,554 Valuation allowance (21,531,017 ) (21,985,554 ) Net deferred income tax asset $ - $ - Deferred income tax liability: Intangible assets $ 742,114 $ 754,698

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities Recorded at Fair Value	The Company uses fair value to measure the value of the banker’s acceptance notes it holds as of December 31, 2023 and 2022. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at December 31, Reporting Date Using Description 2023 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 65,915 $ - $ 65,915 $ - Total $ 65,915 $ - $ 65,915 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2022 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 13,784 $ - $ 13,784 $ - Total $ 13,784 $ - $ 13,784 $ -

Organization and Significant _2

Organization and Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	May 25, 2005
Organization and Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 1,400,000
Accumulated deficit	(39,300,000)
Bad debt expense	15,757	$ 93,851
Uncollectible trade accounts receivable	0	0
Advances from customers	$ 90,507	$ 520,295
Purchase of common stock (in Shares)	13,300
Shares issuable upon conversion of the convertible note payable (in Shares)	6,267
Onny Investment Limited [Member]
Organization and Significant Accounting Policies [Line Items]
Ownership percentage	100%
Hainan Helpson Medical & Biotechnology Co., Ltd [Member]
Organization and Significant Accounting Policies [Line Items]
Ownership percentage	100%		100%
Chief Executive Officer [Member]
Organization and Significant Accounting Policies [Line Items]
Working capital	$ 1,133,809

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventory [Line Items]
Raw materials	$ 1,849,213	$ 1,839,641
Work in process	413,597	557,146
Finished goods	1,469,707	551,000
Total Inventory	$ 3,732,517	$ 2,947,787

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expanse	$ 2,529,858	$ 2,663,975

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 37,495,080	$ 38,323,430
Less: accumulated depreciation	(30,394,655)	(28,350,365)
Property, plant and equipment, net	7,100,425	9,973,065
Permit of land use [Member]
Property, Plant and Equipment [Line Items]
Total	397,684	404,427
Building [Member]
Property, Plant and Equipment [Line Items]
Total	9,234,836	9,391,433
Plant, machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Total	27,170,123	27,780,585
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	303,697	438,138
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 388,740	$ 308,847

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets	Dec. 31, 2023
Permit of land use [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	40 years
Permit of land use [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	70 years
Building [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	20 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	49 years
Plant, machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	5 years
Plant, machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	10 years
Motor vehicle [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	5 years
Motor vehicle [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	10 years
Office equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	3 years
Office equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]
Estimated useful lives	5 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)			12 Months Ended
	Dec. 15, 2023	Nov. 28, 2023	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets (Details) [Line Items]
Amortization intangible by useful life, descriptions			Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
Amortization expense relating to intangible assets			$ 223,796	$ 36,558
Stock issued (in Shares)	3,000,000	310,446
Common stock value	$ 1,650,000	$ 1,707,452
Closing price of common stock (in Dollars per share)	$ 0.55	$ 5.5
Intangible asset useful life,term			9 years 8 months 12 days
Percentage of net profit			15%
Helpson [Member]
Intangible Assets (Details) [Line Items]
Percentage of net profit			15%
China Pharma [Member]
Intangible Assets (Details) [Line Items]
Intangible asset useful life,term			14 years 9 months 18 days

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]
Accumulated amortization	$ (4,890,646)	$ (4,747,142)
Net carrying amount	3,255,232	1,807,486
NMPA approved medical formulas [Member]
Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]
Gross carrying amount	4,766,353	4,847,176
Technology from Bonier [Member]
Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]
Gross carrying amount	1,726,497	1,707,452
Invention Patent [Member]
Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]
Gross carrying amount	$ 1,653,028

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Aggregate Annual Amortization Expense [Abstract]
2024	$ 327,050
2025	321,235
2026	292,156
2027	292,156
2028	292,156
Thereafter	1,730,479
Total	$ 3,255,232	$ 1,807,486

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of Other Payables - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Payables [Line Items]
Compensation payable to officer	$ 1,243,506	$ 951,506
Compensation and interest to related parties	12,000	372,578
Business taxes and other	1,027,186	1,065,979
Total Other Payables	$ 2,282,692	$ 2,390,063

Related Party Transactions (Det

Related Party Transactions (Details)				1 Months Ended	12 Months Ended
	Aug. 23, 2023 USD ($)	Jul. 08, 2019 USD ($)	Jul. 08, 2019 CNY (¥)	Sep. 28, 2023 USD ($) shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Related Party Transactions (Details) [Line Items]
Loan payment	$ 1,854,452
Aggregate amount				$ 1,854,452
Restricted common stock (in Shares) | shares				2,751,412
Term of loan agreement					1 year
Board of Directors Chairman [Member]
Related Party Transactions (Details) [Line Items]
Borrowings from related parties						$ 1,354,567
Interest rate					1%
Other payables					$ 12,000	372,578
Chairperson Li [Member]
Related Party Transactions (Details) [Line Items]
Borrowings from related parties							$ 1,121,273	$ 1,425,123
Interest expense					6,773	13,546
Other payables					1,243,506	951,506
Proceeds from loan agreement		$ 738,379	¥ 4,770,000
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Total advance received					2,928	0
Interim Chief Financial Officer [Member]
Related Party Transactions (Details) [Line Items]
Total advance received					0	223,013
Management [Member]
Related Party Transactions (Details) [Line Items]
Interest rate		4.35%	4.35%
Chief Financial Officer [Member]
Related Party Transactions (Details) [Line Items]
Interest expense					$ 27,644	$ 28,962

Lines of Credit and Construct_3

Lines of Credit and Construction Loan Facility (Details)					1 Months Ended					12 Months Ended
	Oct. 31, 2020 USD ($)	Oct. 31, 2020 CNY (¥)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CNY (¥)	Sep. 28, 2023 USD ($)	Jul. 31, 2020 USD ($)	Jul. 31, 2020 CNY (¥)	Apr. 30, 2020 USD ($)	Apr. 30, 2020 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 02, 2024 CNY (¥)	Dec. 20, 2023 CNY (¥)	Sep. 25, 2023 USD ($)	Sep. 25, 2023 CNY (¥)	Feb. 24, 2023 USD ($)	Feb. 24, 2023 CNY (¥)	Dec. 31, 2022 CNY (¥)	Dec. 30, 2022 USD ($)	Dec. 30, 2022 CNY (¥)	Dec. 21, 2022 USD ($)	Dec. 21, 2022 CNY (¥)	Sep. 30, 2022	Sep. 06, 2022	Jun. 22, 2022	Jun. 21, 2022	Sep. 30, 2021 USD ($)	Sep. 30, 2021 CNY (¥)	Sep. 18, 2021 USD ($)	Sep. 18, 2021 CNY (¥)	Jun. 25, 2021	Sep. 30, 2020 CNY (¥)
Line of Credit Facility [Line Items]
interest rate, percentage										4.25%			3.90%	3.35%	3.35%												4.50%	4.50%
Line of credit, amount													¥ 3,800,000						$ 560,000	¥ 3,800,000	$ 1,000,000	¥ 7,300,000							$ 1,540,000	¥ 10,000,000
Total interest expense										$ 31,750	$ 53,283
Repaid under this line of credit (in Yuan Renminbi)										1,030,680	2,440,915
Advance amount	$ 100,000	¥ 856,660				$ 400,000	¥ 3,000,000	$ 700,000	¥ 5,000,000
Aggregate amount (in Yuan Renminbi)					$ 1,854,452
Repaid amount											0.85							¥ 5,900,000
Loans Payable [Member]
Line of Credit Facility [Line Items]
interest rate, percentage																					3.90%	3.90%			4.17%	4.17%					4.17%
Subsequent Event [Member]
Line of Credit Facility [Line Items]
Repaid under this line of credit (in Yuan Renminbi) | ¥												¥ 3,500,000
Bank of Communications [Member]
Line of Credit Facility [Line Items]
Line of credit, amount																$ 510,000	¥ 3,500,000
China CITIC Bank [Member]
Line of Credit Facility [Line Items]
interest rate, percentage	4.50%	4.50%
Line of credit, amount			$ 500,000																													¥ 3,200,000
Total interest expense										19,579	20,548
Advance amount			$ 300,000	¥ 2,343,340
Percentage of loan bears interest																								4.50%
CITIC Bank [Member]
Line of Credit Facility [Line Items]
Line of credit, amount																											$ 800,000	¥ 3,200,000
Bank of China [Member]
Line of Credit Facility [Line Items]
interest rate, percentage																							3.45%						3.85%	3.85%
Line of credit, amount								$ 1,400,000
Total interest expense										$ 48,624	54,923
Loan and received proceeds														$ 1,400,000	¥ 10,000,000
Aggregate amount (in Yuan Renminbi) | ¥									¥ 10,000,000
Postal Savings Bank of China [Member]
Line of Credit Facility [Line Items]
Total interest expense											$ 12,063

Lines of Credit and Construct_4

Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments - Lines of Credit [Member]	Dec. 31, 2023 USD ($)
Line of Credit Facility [Line Items]
2026	$ 2,442,571
Total	$ 2,442,571

Convertible Note Payable (Detai

Convertible Note Payable (Details)																																																					1 Months Ended	12 Months Ended
	Dec. 18, 2023 shares	Dec. 13, 2023 USD ($) $ / shares	Dec. 01, 2023 shares	Nov. 30, 2023 USD ($) $ / shares shares	Nov. 29, 2023 USD ($) $ / shares	Nov. 07, 2023 shares	Nov. 06, 2023 USD ($) $ / shares	Oct. 17, 2023 USD ($) $ / shares shares	Oct. 13, 2023 shares	Oct. 12, 2023 USD ($) $ / shares	Oct. 09, 2023 shares	Oct. 06, 2023 USD ($) $ / shares	Sep. 13, 2023 shares	Sep. 12, 2023 USD ($) $ / shares	Sep. 06, 2023 shares	Sep. 01, 2023 USD ($) $ / shares	Aug. 22, 2023 shares	Aug. 21, 2023 USD ($) $ / shares	Aug. 11, 2023 shares	Aug. 09, 2023 USD ($) $ / shares	Jun. 27, 2023 shares	Jun. 23, 2023 USD ($) $ / shares	Jun. 13, 2023 shares	Jun. 06, 2023 USD ($) $ / shares	May 25, 2023 shares	May 24, 2023 USD ($) $ / shares	May 03, 2023 shares	May 01, 2023 USD ($) $ / shares	Apr. 13, 2023 USD ($) shares	Apr. 07, 2023 USD ($) $ / shares	Mar. 08, 2023 shares	Mar. 02, 2023 USD ($) $ / shares	Jan. 19, 2023 shares	Jan. 18, 2023 USD ($) $ / shares	Jan. 06, 2023 shares	Jan. 05, 2023 USD ($) $ / shares	Dec. 15, 2022 shares	Dec. 14, 2022 USD ($) $ / shares shares	Dec. 13, 2022 USD ($) $ / shares	Dec. 06, 2022 shares	Dec. 05, 2022 USD ($) $ / shares	Dec. 02, 2022 shares	Dec. 01, 2022 USD ($) $ / shares	Oct. 18, 2022 shares	Oct. 17, 2022 USD ($) $ / shares	Aug. 04, 2022 shares	Aug. 03, 2022 USD ($) $ / shares	Jun. 13, 2022 USD ($) $ / shares shares	Apr. 19, 2022 $ / shares	Mar. 31, 2022 shares	Mar. 30, 2022 USD ($) $ / shares	Mar. 21, 2022 USD ($) $ / shares	Nov. 19, 2021 $ / shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Mar. 23, 2022 shares
Convertible Note Payable [line Items]
Debt extension fee (in Dollars)																													$ 65,639
Note and accrued interest																													2%
Debt redemptions weighted average price																																																						82%
Interest accrues on note, description																																																						Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
Redeem of outstanding note (in Dollars)																																																						$ 500,000
Debt instrument redemption price percentage		82%		82%	82%		82%	82%		82%		82%		82%		82%		82%		82%		82%		82%		82%		85%		85%		85%		85%		85%		85%	85%		85%		85%		85%		85%	85%			85%			82%
Note redeemable into shares (in Shares) | shares																																																						2,159,964
Weighted average price (in Dollars per share) | $ / shares																																																				$ 15.565		$ 0.436
Interest expense (in Dollars)																																																						$ 15,757	$ 93,851
Debt redemption amount (in Dollars)		$ 150,000		$ 115,000	$ 125,000		$ 80,000	$ 115,000		$ 115,000		$ 100,000		$ 75,000		$ 140,000		$ 245,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 150,000		$ 200,000		$ 250,000		$ 250,000		$ 150,000		$ 150,000	$ 90,000		$ 310,000		$ 100,000		$ 100,000		$ 200,000	$ 200,000			$ 200,000	$ 100,000
Share issued (in Shares) | shares																																																								6,425
Common Stock [Member]
Convertible Note Payable [line Items]
Stock issued during period shares (in Shares) | shares	370,828		312,500	339,674		212,444		224,172	224,172		183,150		129,534		210,211		228,652		139,991		105,448		112,952		120,628		113,465		142,450		86,957		65,531		39,319		36,181	19,781		74,789		24,126		17,857		22,792		20,202		12,874
Minimum [Member]
Convertible Note Payable [line Items]
Debt redemptions weighted average price																													85%
Maximum [Member]
Convertible Note Payable [line Items]
Debt redemptions weighted average price																													82%
Convertible Notes Payable [Member]
Convertible Note Payable [line Items]
Note converted into common stock																																																	70,000				176,229	6,267
Conversion price (in Dollars per share) | $ / shares		$ 0.4045		$ 0.368	$ 0.368		$ 0.3765	$ 0.513		$ 0.513		$ 0.546		$ 0.579		$ 0.666		$ 1.0715		$ 1.0715		$ 1.4225		$ 1.328		$ 1.2435		$ 1.322		$ 1.404		$ 2.875		$ 3.815		$ 3.815		$ 4.145	$ 4.55		$ 4.145		$ 4.145		$ 5.6		$ 8.775	$ 9.9			$ 15.645		$ 29.79085	$ 150
Interest expense (in Dollars)																																																						$ 206,744	$ 250,314
China Pharma’s [Member] | Common Stock [Member]
Convertible Note Payable [line Items]
Conversion price (in Dollars per share) | $ / shares																																																	$ 75
China Pharma’s [Member] | Convertible Notes Payable [Member]
Convertible Note Payable [line Items]
Note converted into common stock																																																						35,000

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease cost	$ 77,265	$ 78,092
Operating lease payments	80,647	82,015
Operating lease right of use assets	116,610	39,046
Operating use liabilities	$ 117,637	$ 40,445
Operating lease weighted average lease term	1 year 6 months
Operating lease weighted average discount rate	4.75%

Leases (Details) - Schedule of

Leases (Details) - Schedule of Operating Lease Liabilities - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Operating Lease Liabilities [Abstract]
2024	$ 80,647
2025	40,324
Total undiscounted cash flows	120,971
Less: Imputed interest	(3,334)
Total	117,637
Less: Operating lease liabilities, current portion	(77,727)	$ (40,445)
Operating lease liabilities, net of current portion	$ 39,910

Income Taxes (Details)

Income Taxes (Details) - USD ($)		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Enterprise income tax rate		25%
Operating loss carryforwards			$ 21,100,000
Operating loss carryforwards available for future taxable income		$ 5,100,000
Operating loss carryforwards limitations, descriptions		through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year
Maximum [Member]
Income Taxes [Line Items]
U.S. federal corporate income tax rate	35%
Valuation allowance on deferred tax assets		$ 21,531,017
Minimum [Member]
Income Taxes [Line Items]
U.S. federal corporate income tax rate	21%
Valuation allowance on deferred tax assets			$ 21,467,355
Tax Year 2023 [Member]
Income Taxes [Line Items]
Operating loss carryforwards		3,400,000
United States Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards		$ 9,900,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]
(Benefit) tax at statutory rate of 25%	$ (769,704)	$ (973,717)
Prior year refund received
Other, primarily the difference in U.S. tax rates	3,382	8,416
Change in valuation allowance	766,322	965,301
Income tax expense

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]
(Benefit) tax at statutory rate	25%	25%

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred income tax assets:
Allowance for doubtful trade receivables	$ 3,446,519	$ 4,184,882
Allowance for doubtful other receivables	6,754	6,787
Inventory obsolescence reserve	32,355	34,921
Stock compensation	3,201	3,201
Expenses not deductible in current year	1,069,198	1,087,328
Advances for intangible assets impairment	9,619,060	9,782,172
Lease liability, net	257	349
PRC net operating loss carry forward	5,275,411	5,036,114
U.S. net operating loss carry forward	2,078,262	1,849,800
Total deferred income tax assets	21,531,017	21,985,554
Valuation allowance	(21,531,017)	(21,985,554)
Net deferred income tax asset
Deferred income tax liability:
Intangible assets	$ 742,114	$ 754,698

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	$ 65,915	$ 13,784
Banker's Acceptance Notes [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	65,915	13,784
Level 1 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Level 1 [Member] | Banker's Acceptance Notes [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Level 2 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	65,915	13,784
Level 2 [Member] | Banker's Acceptance Notes [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total	65,915	13,784
Level 3 [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total
Level 3 [Member] | Banker's Acceptance Notes [Member]
Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)				12 Months Ended
	Oct. 04, 2022	Oct. 03, 2022	Sep. 09, 2021	Dec. 31, 2023	Dec. 17, 2023	Dec. 31, 2022	Dec. 27, 2022	Dec. 27, 2021	Dec. 23, 2020
Stockholders' Equity [Line Items]
Common stock, shares authorized				500,000,000		500,000,000
Common stock, par value (in Dollars per share)				$ 0.001		$ 0.001
Preferred stock, shares authorized				5,000,000		5,000,000
Preferred stock, par value (in Dollars per share)				$ 0.001		$ 0.001
After tax income, percentage				10%
Reserve account balances, percentage				50%
General and statutory capital reserves amount (in Dollars)				$ 8,145,000		$ 8,145,000
Common stock reserved shares							100,000	100,000
Total option outstanding				13,300
Additional shares available for issuance				482,000
Compensation expense (in Dollars)		$ 42,000
Closing market price (in Dollars per share)	$ 7.5	$ 7	$ 33.5
Additional shares of common stock		18,000
Purchase of common stock	12,000		1,300
Exercise price of per share (in Dollars per share)	$ 28		$ 73.7
Options granted (in Dollars)	$ 36,270		$ 15,243
Percentage of volatility	115.50%		118.40%
Percentage of risk free interest rate	3.84%		0.75%
Expected life, term	2 years 6 months		1 year 6 months
Issued an aggregate			35,200
Price of per share (in Dollars per share)			$ 33.5
Unpaid cash (in Dollars)			$ 1,179,200						$ 864,480
Effective March 6, 2024 [Member]
Stockholders' Equity [Line Items]
Reverse stock split, description				1-for -5
Effective March 6, 2023 [Member]
Stockholders' Equity [Line Items]
Reverse stock split, description				1-for-10
2010 Incentive Plan [Member]
Stockholders' Equity [Line Items]
Common stock issued				580,000
Stock and stock option granted and outstanding				84,700
Minimum [Member]
Stockholders' Equity [Line Items]
Common stock reserved shares					280,000		180,000	80,000
Maximum [Member]
Stockholders' Equity [Line Items]
Common stock reserved shares					580,000		280,000	180,000
Common Stock [Member]
Stockholders' Equity [Line Items]
Issuance of common stock		6,000							40,000

Risks & Uncertainties (Details)

Risks & Uncertainties (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	10%	10%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	62.59%	52.90%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	13.50%	11.40%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage		10.40%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	29.20%	25%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	27.30%	22.80%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	12.50%	13.90%
Suppliers One [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage	13.80%	21.70%
Suppliers Two [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]
Risks & Uncertainties (Details) [Line Items]
Concentration risk percentage		11.10%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)				12 Months Ended
	Feb. 16, 2024	Feb. 01, 2024	Jan. 11, 2024	Dec. 31, 2023	Feb. 21, 2024	Feb. 05, 2024	Jan. 16, 2024	Dec. 31, 2022
Subsequent Events [Line Items]
Aggregate transfer price				$ 1.365
Issuance of shares of common stock				6,267
Common stock per share based				$ 0.455
Redemption percentage				10%
Share issued				10,625,788				1,498,180
Common Stock [Member]
Subsequent Events [Line Items]
Issuance of shares of common stock				3,000,000
Subsequent Event [Member]
Subsequent Events [Line Items]
Redemption amount	$ 150,000	$ 150,000	$ 150,000
Redemption of weighted average percentage	82%	82%	82%
Subsequent Event [Member] | Common Stock [Member]
Subsequent Events [Line Items]
Share issued						402,685	380,228
Convertible Notes Payable [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Conversion price	$ 0.3675	$ 0.3725	$ 0.3945
Investor [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Events [Line Items]
Share issued					408,164